Eli Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program EP News Bureau Jan 14, 2025 TX-478 could potentially address 30-40 per cent of people with hormone-positive breast cancer, building on Lilly's advancements…
